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Research Highlights 
 
 Antenatal glucocorticoids are given to mothers at risk for preterm delivery 
 There are no known benefits of glucocorticoid treatment in term-born children 
 Full term children with glucocorticoid treatment displayed altered HPA axis 
functioning 
 Antenatal glucocorticoids were associated with lack of a CAR and a flattened 
diurnal slope 
 
Abstract: 
Due to the rapid developmental changes that occur during the fetal period, prenatal influences can 
affect the developing central nervous system with lifelong consequences for physical and mental health. 
Glucocorticoids are one of the proposed mechanisms by which fetal programing occurs. Glucocorticoids 
pass through the blood-brain barrier and target receptors throughout the central nervous system. Unlike 
endogenous glucocorticoids, synthetic glucocorticoids readily pass through the placental barrier to reach 
the developing fetus. The synthetic glucocorticoid, betamethasone, is routinely given prenatally to 
mothers at risk for preterm delivery. Over 25% of the fetuses exposed to betamethasone will be born at 
term. Few studies have examined the lasting consequences of antenatal treatment of betamethasone on the 
regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The purpose of this study is to examine 
whether antenatal exposure to betamethasone alters circadian cortisol regulation in children who were 
born full term. School-aged children prenatally treated with betamethasone and born at term (n=19, mean 
(SD) = 8.1 (1.2) years old) were compared to children not treated with antenatal glucocorticoids (n=61, 
mean (SD) = 8.2 (1.4) years old). To measure the circadian release of cortisol, saliva samples were 
collected at awakening; 30, 45, and 60 minutes after awakening; and in the evening. Comparison children 
showed a typical diurnal cortisol pattern that peaked in the morning (the cortisol awakening response) and 
gradually decreased throughout the day. In contrast, children exposed to antenatal betamethasone lacked a 
cortisol awakening response and had a flatter diurnal slope (p’s <0.01). These data suggest that antenatal 
glucocorticoid treatment may disrupt the circadian regulation of the HPA axis among children born at 
term. Because disrupted circadian regulation of cortisol has been linked to mental and somatic health 
problems, future research is needed to determine whether children exposed to antenatal synthetic 
glucocorticoids are at risk for poor mental and physical health. 
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1. Introduction: 
The rapid developmental changes that occur during the fetal period are unmatched at any other 
stage of life.  Because of the extraordinary pace of fetal development, the fetus is highly vulnerable to the 
consequences of stress exposure (Bourgeois, 1997). Prevailing models of early life stress propose that 
exposure to excess glucocorticoids is a key factor that shapes development of neural systems with lifelong 
consequences for physical and mental health (Moisiadis and Matthews, 2014a). Although there is 
extensive support for this model from experimental animal studies (Matthews, 2000), our understanding 
of the effects of antenatal glucocorticoid exposure on human neurodevelopment is limited. 
For a number of reasons, glucocorticoids are a candidate mechanism underlying fetal 
programming. Glucocorticoids exert a wider array of metabolic, endocrine, and immune effects than any 
other biological ligand (Chrousos and Kino, 2009). Furthermore, glucocorticoids pass through the blood–
brain barrier, target receptors throughout the central nervous system, and play a central role in normal 
brain development (Jacobson and Sapolsky, 1991). Although glucocorticoids are necessary for normative 
fetal brain development, exposure to excessive levels may disrupt basic neurodevelopmental processes 
including dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis (Buss et al., 2012). The risk 
may be even greater when glucocorticoids are administered exogenously, as they are to women in preterm 
labor, thus exposing the fetus to supraphysiologic levels.  
Synthetic glucocorticoids, such as betamethasone, are routinely given as part of the standard of 
care to women who are at risk of delivery between 24 and 34 gestational weeks to reduce respiratory 
distress and increase survival among infants born preterm (McKinlay et al., 2012; American College of 
Obstetricians and Gynecologists, 2011).  Unlike cortisol, betamethasone is not metabolized or inactivated 
by the placental enzyme 11-beta hydroxysteroid dehydrogenase and thereby crosses the placenta more 
readily to act directly on the developing fetus (Albiston et al., 1994; Kajantie et al., 2004). The benefits 
for lung maturation and survival among preterm infants are undisputed.  However, the persisting 
consequences of antenatal glucocorticoids for neurodevelopment remain poorly understood.  Preterm 
birth is associated with increased risk for a wide range of neurodevelopmental consequences (Espel et al., 
2014; Grunau et al., 2005).  Thus, the effects of antenatal glucocorticoid treatment may best be observed 
among healthy children born at term independent of the neurodevelopmental effects of preterm delivery.  
Due to successful medical interventions and the difficulty of predicting who will deliver preterm, 25% to 
30% of women who receive glucocorticoid treatment deliver at term (Davis et al., 2009). Recent studies 
have demonstrated that among children born full term, fetal exposure to glucocorticoid treatment is 
associated with restricted fetal growth (Davis et al., 2009), cortical thinning (Davis et al., 2013) and 
memory impairments (Grant et al., 2015).  
One pathway by which antenatal glucocorticoid exposure is thought to influence later childhood 
outcomes is through altering the development of the fetal HPA axis. Term neonates treated with antenatal 
glucocorticoids have a larger cortisol response to the painful stress of the heel-stick blood draw when 
compared to term neonates without antenatal glucocorticoid treatment (Davis et al., 2011).  The effects of 
antenatal glucocorticoids persist into childhood and are associated with increased cortisol reactivity to a 
social stress test (Alexander et al., 2012; Erni et al., 2012). These studies suggest that antenatal 
glucocorticoid treatment has long-lasting effects on the HPA axis response to stress. Less is known, 
however, about the effects of antenatal glucocorticoid treatment on circadian cortisol regulation. The 
HPA axis releases cortisol in a circadian pattern. Cortisol concentrations typically peak 30-45 minutes 
after awakening (the cortisol awakening response; CAR) and then gradually decline across the day. The 
CAR is a response to awaking (Clow et al., 2010; Wilhelm et al., 2007). Compelling evidence exists that 
the CAR is affected by exposure to early adversity including prenatal maternal depression and anxiety 
(Antonini et al., 2000; Lee et al., 2014; O'Donnell et al., 2013; Stalder et al., 2013). Further, among 
children who were born preterm, postnatal glucocorticoid treatment is associated with a blunted CAR 
during adolescence (Ter Wolbeek et al., 2015).  During the prenatal period, evidence suggests that 
glucocorticoids shape the development of the fetal HPA axis. The offspring of mothers who received 
chronic prednisone treatment for rheumatoid arthritis throughout their pregnancy display altered circadian 
cortisol production and higher cortisol output over the day (de Steenwinkel et al., 2014). Studies 
evaluating the association between early adversity and prematurity and development of the CAR indicate 
that prenatal glucocorticoid treatment may affect HPA axis development and be associated with a 
blunting of the CAR. The current study investigates whether antenatal betamethasone treatment is 
associated with altered diurnal cortisol patterns among school-aged children who were born full term. 
2. Material and Methods: 
2.1. Participants 
 Participants included 111 children, aged 6 to 10 who were born at term, and their mothers 
recruited using delivery records from a major medical center in Southern California. All children were 
full term at birth (gestational age more than 37 weeks based on American College of Obstetricians and 
Gynecologists, 2009, dating criteria; (American College of Obstetricians and Gynecologists, 2009)).  
Child inclusion criteria were appropriate weight for gestational age and singleton status. Exclusion criteria 
included child chromosomal or other congenital anomalies (e.g., trisomy 21), child exposure to postnatal 
systemic steroids, major neonatal illness (e.g., sepsis), maternal preeclampsia or HELLP (hemolysis, 
elevated liver enzymes, and low platelet count) syndrome, maternal drug use, and maternal disorders 
during pregnancy requiring corticosteroid treatment. Seven percent of glucocorticoid-exposed children 
and 5% from the comparison group failed to meet eligibility criteria and were not recruited. 
 Eligible participants were placed in two groups: those who received antenatal treatment with the 
glucocorticoid betamethasone due to risk of preterm delivery and those not treated with antenatal 
glucocorticoids (comparison group). Of those contacted, 86% of glucocorticoid exposed and 63% of 
nonexposed mother-child pairs consented to participate. Of the 26 glucocorticoid-exposed children, 4 
declined participating in the home saliva sample collection and 3 participants provided data that was 
unusable because 3 or more time points were missing or of poor quality. Of the 85 comparison 
participants, 18 declined participating in home sample collection and 6 provided data that was unusable 
because 3 or more time points were missing or of poor quality. The glucocorticoid group consisted of 19 
children born full term who received antenatal glucocorticoid treatment (betamethasone). Consistent with 
standard clinical practice, betamethasone was given via two intramuscular injections 24 hours apart 
between 24 and 34 gestational weeks (M = 30.1 weeks, SD = 3.1). The comparison group consisted of 61 
children born full term and without antenatal exposure to synthetic glucocorticoids. We over recruited 
children in the comparison group to create a more stable characterization of child HPA axis regulation 
among unexposed children. The institutional review boards for protection of human subjects approved the 
study protocol. Written and informed consent from the mother and informed assent from the child were 
obtained before study enrollment. 
2.2. Background Information  
Sociodemographic characteristics were determined at the time of study entry by maternal 
interview. Children’s general intelligence was assessed using the Perceptual Reasoning Index (PRI) of the 
Wechsler Intelligence Scale for Children (WISC-IV). The PRI is relatively language free and two of its 
subscales (Matrix Reasoning and Block Design) have been shown to be excellent indicators of general 
intelligence (Wechsler, 2002). Scores between 90 and 109 are considered average. Child global health 
was assessed with the 5-item global health scale from the MacArthur Health and Behavior Questionnaire 
(Armstrong and Goldstein, 2003).  Possible scores ranged from 0 excellent health to 3 poor health. Child 
experience of life events was evaluated using the Coddington Life Events Checklist for Elementary 
School Aged Children (Coddington, 1972).  This measure assesses both positive (e.g., "outstanding 
personal achievement") and negative (e.g., parental divorce) life events.  Total score on this measure 
could range from 0 to 33.  Maternal intellectual performance was determined by the Perceptual 
Organization Index (POI) of the Wechsler Adult Intelligence Scale (Wechsler, 1997). Scores between 90 
and 109 are considered average. Maternal depression was evaluated with the Beck Depression Inventory 
II (BDI; Beck et al., 1996). Scores could range from 0 to 63 (14-19 mild depression; 20-28 moderate 
depression; 29-63 severe depression). Obstetric and neonatal medical characteristics, including birth 
outcome data, were determined by medical record abstraction.  
2.3. Salivary Cortisol Assessment  
Mothers collected saliva samples from their children five times over the course of one weekday at 
home.  Samples were collected four times in the morning (at awakening and 30, 45, and 60 minutes after 
waking) and once in the evening (at 2000h).  Salivary cortisol reflects the unbound or free cortisol and is 
highly correlated with plasma cortisol (Gunnar et al., 1989; Kirschbaum and Hellhammer, 1989). For 
each sample, a small, absorbent swab was placed in the child's mouth for approximately 30 seconds.  The 
swab was then placed into the Swab Extraction Tube System (S.E.T.S., Roche Diagnostics) and returned 
to the lab by mail.  Collection swabs were kept in Medication Event Monitoring System (MEMS)® 6 
TrackCaps which recorded each date and time the cap was opened to remove a swab. Mothers were also 
asked to fill out a short survey including questions about sample collection time, awakening time, their 
child's sleep habits and health status. None of the samples were collected on days when the child was 
febrile. Mothers reported that medication use included analgesics (n=1), antibiotics (n=2) and an 
expectorant (n=1), Inclusion of these children did not alter study findings and thus they were included in 
analyses. Once returned to the lab, samples were spun in a centrifuge at 5,500 rpm for 15 minutes to 
extract saliva from the collection swab.  Samples were stored at -20°C until assayed. Salivary cortisol 
levels were determined by a competitive luminescence immunoassay (LIA; IBL-America, Minneapolis, 
MN) with detection limits of 0.138 nmol/L. The intra- and inter-assay coefficients of variance are 5.5% 
and 7.6%, respectively. All samples were assayed in duplicate and averaged. For each time point, samples 
that were above 3 standard deviations above the mean were removed.  
2.4. Data Analysis 
Fisher exact and one-way analysis of variance tests were used to determine whether child 
(intelligence, health, experience of life events, race/ethnicity; sex; birth order; gestational age at birth; 
birth weight percentile; Apgar score; age at assessment; and time of awakening) or maternal (cohabitation 
status; cohabitation with the child’s father; education level; household income; age at delivery; 
intelligence; and depression level) characteristics differed between groups. Of these potential confounding 
factors, only gestational age at birth significantly differed between groups and thus was included as a 
covariate in all analyses.  Because CAR was a primary outcome of interest, time of awakening was 
additionally included as a covariate. We used multiple imputations (n=10 datasets) as a strategy to 
manage the missing data, which consisted of 2 cortisol values, 5 collection times, and 3 awakening times 
(Little, 2002). No participants were missing more than 2 values. Cortisol values were positively skewed at 
all sampling periods and thus a square root transformation was applied. Data transformation did not alter 
the results, thus the untransformed data is reported in nanomoles per liter (nmol/L) to improve 
interpretability.  
 Multilevel modeling using hierarchical linear modeling (HLM) growth curve analysis was 
conducted to assess the association between antenatal betamethasone exposure and children’s diurnal 
cortisol (Raudenbush, 2002). Initial testing indicated that a piecewise model provided the best fit for 
diurnal cortisol patterns. To create the piecewise model, data for each individual was split into two 
discrete phases, before and after their maximum cortisol value 30-45 minutes after awakening.  In the full 
two-level model, the effects of betamethasone exposure on cortisol levels at awakening, the CAR, and the 
diurnal cortisol slope were examined. Specifically, the Level 1 variables (or the time-variant variables) 
included the cortisol values at each sample collection and the time of the sample collection in hours. The 
Level 2 variables (or time-invariant variables) included betamethasone exposure and relevant covariates 
(time of awakening and GAB).  
3. Results: 
As described in table 1, children were predominantly Hispanic or non-Hispanic white, of average 
intelligence, and of good physical health.  Median income in this sample was 55,000 and mothers were 
predominantly cohabitating with the child’s father (82.5%) (See Table 2). Although only term-born 
children were included in this study, those treated with betamethasone had a younger gestational age at 
birth compared to those who did not receive glucocorticoids (38.5wks vs. 39.4wks; Table 1). The 
betamethasone group did not significantly differ from the comparison group on any other child 
(intelligence, child health, exposure to life events, race/ethnicity; sex; birth order; gestational age at birth; 
birth weight percentile; Apgar score; age at assessment; and time of awakening) or maternal (cohabitation 
status; cohabitation with the child’s father; education level; household income; age at delivery; 
intelligence; and maternal depression level) characteristics (all p’s >0.05, Tables 1 & 2).  
Cortisol values for the betamethasone and comparison groups are illustrated in Figure 1. Children 
exposed to antenatal betamethasone failed to show a CAR and exhibited a flatter diurnal slope than the 
comparison participants (βCAR=-3.44, p<0.05; βdiurnal=0.19, p<0.05; Table 3).  These associations were 
strengthened when gestational age at birth and time of awakening included as covariates (βCAR =-4.77, 
p<0.01, βdiurnal =0.23, p<0.01; Table 3). Figure 2 depicts the HLM modeled influence of betamethasone on 
cortisol levels after accounting for covariates. Gestational age at the time of betamethasone treatment was 
not associated with diurnal cortisol regulation (p=0.80). 
4. Discussion: 
 The current study provides new evidence that antenatal glucocorticoid treatment is associated 
with persisting alterations in diurnal cortisol regulation among school-aged children. Children exposed to 
betamethasone during fetal development lacked a cortisol awakening response and had a flatter diurnal 
slope than children that were not treated with antenatal glucocorticoids. Interestingly, the diurnal cortisol 
profile, characterized by lack of a cortisol awakening response and a flattened diurnal slope, is similar to 
that seen among children experiencing prenatal (O'Donnell et al., 2013) or postnatal (Koss et al., 2014) 
adversity. The association between prenatal glucocorticoid treatment and diurnal cortisol regulation was 
observed among children who were born full term and persisted after considering potential covariates.  
 Our findings are consistent with a recent study by Ter Wolbeek and colleagues (2015) 
demonstrating that postnatal glucocorticoids are associated with a flattened CAR among children who 
were born preterm.  Premature delivery is associated with HPA axis dysregulation (Lee et al., 2014).  Our 
observation that antenatal glucocorticoids are associated with a flattened CAR among children born full 
term provides important new evidence that glucocorticoid treatment is associated with HPA axis 
development independent of birth outcome.  In conjunction with prior human research indicating that 
antenatal glucocorticoid treatment is associated with dysregulated cortisol responses to stress (Alexander 
et al., 2012; Davis et al., 2004; Davis et al., 2006; Davis et al., 2011; de Steenwinkel et al., 2014; Erni et 
al., 2012; Ter Wolbeek et al., 2015), these data suggest that antenatal glucocorticoid treatment exerts long 
term programming consequences on HPA axis development.  The extant literature has relied on 
correlational designs.  Future research should evaluate children who were part of randomized controlled 
trials for prenatal glucocorticoid treatment (Gyamfi-Bannerman et al., 2016). Long term follow up of 
children who received glucocorticoids as part of an experimental design is needed to fully determine the 
neurodevelopmental influence of prenatal glucocorticoid treatment. 
It is plausible that the alterations to diurnal cortisol regulation we observed among children who 
received antenatal glucocorticoids indicate risk for poor physical and mental health outcomes. 
Neurological advances in middle childhood include synaptic pruning and myelination (Muftuler et al., 
2011; Muftuler et al., 2012).  These neurodevelopmental processes may be influenced by cortisol 
exposure.  Although cortisol levels tend to be lower in middle childhood as compared to adolescence, 
there is evidence for individual stability in diurnal cortisol regulation from childhood to adolescence 
(Shirtcliff et al., 2012).  Thus, children with antenatal betamethasone may continue to show dysregulated 
cortisol production into adolescence.   
A flattened CAR and diurnal slope may indicate risk for metabolic disease or psychiatric dysfunction. 
Toddlers with a blunted CAR are more likely to have delays in cognitive functioning (Saridjan et al., 
2014a). Children and adults with lower morning cortisol and a flatter diurnal slope have higher levels of 
internalizing problems (Bhattacharyya et al., 2008; Ruttle et al., 2011; Saridjan et al., 2014b) and in 
adulthood disrupted circadian cortisol regulation is associated with risk for metabolic, cardiac, and 
autoimmune diseases (Chikanza et al., 1992; Matthews et al., 2006; Rosmond and Bjorntorp, 1998). 
Because a blunted CAR and a flat diurnal cortisol slope are associated with health risks, additional 
research is needed to determine the long-term consequences. The massive developmental changes 
occurring during gestation render the fetus vulnerable to exposures including elevated glucocorticoids. 
Glucocorticoids cross the blood-brain barrier and influence fetal neurogenesis, synaptogenesis, and 
myelination (McCabe et al., 2001; Moisiadis and Matthews, 2014b). These effects of glucocorticoids are 
greatest in regions that contain the highest levels of glucocorticoid receptors, such as the amygdala, 
hippocampus, and prefrontal cortex (Diorio et al., 1993; Jacobson and Sapolsky, 1991; Sanchez et al., 
2000). During the gestational period when glucocorticoids are administered neurodevelopmental 
processes include neuronal differentiation, dendritic arborization, axonal elongation, synapse formation 
and collateralization, and myelination (Bourgeois, 1997; Volpe, 2008). Further, glucocorticoid receptors 
are present in the human hippocampus at by 24 gestational weeks rendering the fetal brain susceptible to 
glucocorticoids (Noorlander et al., 2006). By altering the development of hypothalamic, limbic, and 
cortical regions that play a central role in HPA axis regulation, antenatal glucocorticoids may exert 
persisting consequences on child HPA axis functioning. For example, glucocorticoids may downregulate 
the fetal HPA axis by activating epigenetic and feedback mechanisms that affect glucocorticoid receptors 
(Moisiadis and Matthews, 2014b).  Fewer glucocorticoid receptors may result in desensitization of the 
HPA axis and a reduction in morning cortisol production (Jarcho et al., 2013). Fetal exposure to high 
levels of glucocorticoids may modify the development of the HPA axis and its regulatory brain regions 
resulting in alterations to diurnal cortisol regulation.  
This study has several strengths. We examined healthy children 8-10 years of age who were full term 
at birth. Additionally, adherence to the cortisol sampling procedure was evaluated using both maternal-
report and the Medication Event Monitoring System (MEMS), which records the time of sample 
collection. This technology allowed us to ensure good compliance, which is especially critical when 
measuring time-sensitive cortisol levels. A primary limitation of the present investigation is that 
betamethasone treatment was not randomly assigned, and thus we cannot rule out the possibility of 
confounding factors.  It is plausible that unmeasured prenatal experiences that related to the reason for 
betamethasone treatment contributed to group differences that affect HPA axis development. Further, 
because women and children were not prospectively evaluated during the prenatal period, we were not 
able to characterize other aspects of the prenatal environment (e.g. maternal stress, maternal cortisol) that 
may influence fetal HPA axis development. However, we examined several potential covariates. Groups 
differed on gestational age of birth, but not differ on other key clinical and demographic factors (Tables 1 
and 2).  
 Our findings extend the existing literature by evaluating children born healthy and full term. Our 
results show that antenatal exposure to a single course of betamethasone is associated with absence of a 
cortisol awakening response and flat diurnal slope. Future research is needed to understand the clinical 
implications for health and development across the lifespan. 
  
All authors have participated in the research and article preparation. EPD conceived and designed the 
study and acquired the data. MNE, EPD, CAS, and LMG analyzed the data. All authors contributed to the 
interpretation of the data, drafted or revised the manuscript, and have approved the final article. 
 
 
5. Acknowledgments  
We sincerely thank the families who participated in this study. The assistance of Megan Faulkner, Natalie 
Hernandez, and Kendra Leak are gratefully recognized. This research was supported by the National 
Institutes of Health Awards HD050662 and HD065823 to EPD and Conte Center Award MH096889. 
This research was supported by the National Institutes of Health Awards HD050662 and HD065823 to 
EPD and Conte Center Award MH-96889. The sponsors had no involvement in the study design; 
collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the 
article for publication. 
  
 6. References 
Albiston, A.L., Obeyesekere, V.R., Smith, R.E., Krozowski, Z.S., 1994. Cloning and tissue distribution of 
the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105, R11-17. 
Alexander, N., Rosenlocher, F., Stalder, T., Linke, J., Distler, W., Morgner, J., Kirschbaum, C., 2012. 
Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. 
J Clin Endocrinol Metab 97, 3538-3544. 
American College of Obstetricians and Gynecologists, 2009. ACOG Practice Bulletin No. 101: 
Ultrasonography in pregnancy. Obstet Gynecol 113, 451-461. 
American College of Obstetricians and Gynecologists, 2011. ACOG Committee Opinion No. 475: 
Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 117, 422-424. 
Antonini, S.R., Jorge, S.M., Moreira, A.C., 2000. The emergence of salivary cortisol circadian rhythm 
and its relationship to sleep activity in preterm infants. Clin Endocrinol (Oxf) 52, 423-426. 
Armstrong, J.M., Goldstein, L.H., 2003. Manual for the MacArthur Health and Behavior Questionnaire 
(HBQ 1.0). University of Pittsburgh. 
Beck, A.T., Steer, R.A., Brown, G.K., 1996. Manual for the Beck Depression Inventory—II. The 
Psychological Corporation, San Antonio, TX. 
Bhattacharyya, M.R., Molloy, G.J., Steptoe, A., 2008. Depression is associated with flatter cortisol 
rhythms in patients with coronary artery disease. J Psychosom Res 65, 107-113. 
Bourgeois, J.P., 1997. Synaptogenesis, heterochrony and epigenesis in the mammalian neocortex. Acta 
Paediatr Suppl 422, 27-33. 
Buss, C., Davis, E.P., Shahbaba, B., Pruessner, J.C., Head, K., Sandman, C.A., 2012. Maternal cortisol 
over the course of pregnancy and subsequent child amygdala and hippocampus volumes and affective 
problems. Proc Natl Acad Sci U S A 109, E1312-1319. 
Chikanza, I.C., Petrou, P., Kingsley, G., Chrousos, G., Panayi, G.S., 1992. Defective hypothalamic 
response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 35, 
1281-1288. 
Chrousos, G.P., Kino, T., 2009. Glucocorticoid signaling in the cell. Expanding clinical implications to 
complex human behavioral and somatic disorders. Ann N Y Acad Sci 1179, 153-166. 
Clow, A., Hucklebridge, F., Stalder, T., Evans, P., Thorn, L., 2010. The cortisol awakening response: 
more than a measure of HPA axis function. Neurosci Biobehav Rev 35, 97-103. 
Coddington, R.D., 1972. The significance of life events as etiologic factors in the diseases of children. II. 
A study of a normal population. J Psychosom Res 16, 205-213. 
Davis, E.P., Sandman, C.A., Buss, C., Wing, D.A., Head, K., 2013. Fetal glucocorticoid exposure is 
associated with preadolescent brain development. Biol Psychiatry 74, 647-655. 
Davis, E.P., Townsend, E.L., Gunnar, M.R., Georgieff, M.K., Guiang, S.F., Ciffuentes, R.F., Lussky, 
R.C., 2004. Effects of prenatal betamethasone exposure on regulation of stress physiology in healthy 
premature infants. Psychoneuroendocrinology 29, 1028-1036. 
Davis, E.P., Townsend, E.L., Gunnar, M.R., Guiang, S.F., Lussky, R.C., Cifuentes, R.F., Georgieff, M.K., 
2006. Antenatal betamethasone treatment has a persisting influence on infant HPA axis regulation. J 
Perinatol 26, 147-153. 
Davis, E.P., Waffarn, F., Sandman, C.A., 2011. Prenatal treatment with glucocorticoids sensitizes the hpa 
axis response to stress among full-term infants. Dev Psychobiol 53, 175-183. 
Davis, E.P., Waffarn, F., Uy, C., Hobel, C.J., Glynn, L.M., Sandman, C.A., 2009. Effect of prenatal 
glucocorticoid treatment on size at birth among infants born at term gestation. J Perinatol 29, 731-737. 
de Steenwinkel, F.D., Hokken-Koelega, A.C., Hazes, J.M., Dolhain, R.J., 2014. The influence of foetal 
prednisone exposure on the cortisol levels in the offspring. Clin Endocrinol (Oxf) 80, 804-810. 
Diorio, D., Viau, V., Meaney, M.J., 1993. The role of the medial prefrontal cortex (cingulate gyrus) in the 
regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 13, 3839-3847. 
Erni, K., Shaqiri-Emini, L., La Marca, R., Zimmermann, R., Ehlert, U., 2012. Psychobiological effects of 
prenatal glucocorticoid exposure in 10-year-old-children. Front Psychiatry 3, 104. 
Espel, E.V., Glynn, L.M., Sandman, C.A., Davis, E.P., 2014. Longer gestation among children born full 
term influences cognitive and motor development. PLoS One 9, e113758. 
Grant, K.A., Sandman, C.A., Wing, D.A., Dmitrieva, J., Davis, E.P., 2015. Prenatal programming of 
postnatal susceptibility to memory impairments: A developmental double jeopardy. Psychol Sci 26, 1054-
1062. 
Grunau, R.E., Holsti, L., Haley, D.W., Oberlander, T., Weinberg, J., Solimano, A., Whitfield, M.F., 
Fitzgerald, C., Yu, W., 2005. Neonatal procedural pain exposure predicts lower cortisol and behavioral 
reactivity in preterm infants in the NICU. Pain 113, 293-300. 
Gunnar, M.R., Connors, J., Isensee, J., 1989. Lack of stability in neonatal adrenocortical reactivity 
because of rapid habituation of the adrenocortical response. Dev Psychobiol 22, 221-233. 
Gyamfi-Bannerman, C., Thom, E.A., Blackwell, S.C., Tita, A.T., Reddy, U.M., Saade, G.R., Rouse, D.J., 
McKenna, D.S., Clark, E.A., Thorp, J.M., Jr., Chien, E.K., Peaceman, A.M., Gibbs, R.S., Swamy, G.K., 
Norton, M.E., Casey, B.M., Caritis, S.N., Tolosa, J.E., Sorokin, Y., VanDorsten, J.P., Jain, L., Network, 
N.M.-F.M.U., 2016. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J 
Med 374, 1311-1320. 
Jacobson, L., Sapolsky, R., 1991. The role of the hippocampus in feedback regulation of the 
hypothalamic-pituitary-adrenocortical axis. Endocr Rev 12, 118-134. 
Jarcho, M.R., Slavich, G.M., Tylova-Stein, H., Wolkowitz, O.M., Burke, H.M., 2013. Dysregulated 
diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive 
disorder. Biol Psychol 93, 150-158. 
Kajantie, E., Raivio, T., Janne, O.A., Hovi, P., Dunkel, L., Andersson, S., 2004. Circulating 
glucocorticoid bioactivity in the preterm newborn after antenatal betamethasone treatment. J Clin 
Endocrinol Metab 89, 3999-4003. 
Kirschbaum, C., Hellhammer, D.H., 1989. Salivary cortisol in psychobiological research: an overview. 
Neuropsychobiology 22, 150-169. 
Koss, K.J., Hostinar, C.E., Donzella, B., Gunnar, M.R., 2014. Social deprivation and the HPA axis in 
early development. Psychoneuroendocrinology 50, 1-13. 
Lee, J., Fried, R., Thayer, Z., Kuzawa, C.W., 2014. Preterm Delivery as a Predictor of Diurnal Cortisol 
Profiles in Adulthood: Evidence from Cebu, Philippines. American Journal of Human Biology 26, 598-
602. 
Little, R.J.A.R., D.B., 2002. Statistical Analysis with Missing Data. John Wiley & Sons, Inc, Hoboken, 
New Jersey. 
Matthews, K., Schwartz, J., Cohen, S., Seeman, T., 2006. Diurnal cortisol decline is related to coronary 
calcification: CARDIA study. Psychosom Med 68, 657-661. 
Matthews, S.G., 2000. Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res 
47, 291-300. 
McCabe, L., Marash, D., Li, A., Matthews, S.G., 2001. Repeated antenatal glucocorticoid treatment 
decreases hypothalamic corticotropin releasing hormone mRNA but not corticosteroid receptor mRNA 
expression in the fetal guinea-pig brain. J Neuroendocrinol 13, 425-431. 
McKinlay, C.J., Crowther, C.A., Middleton, P., Harding, J.E., 2012. Repeat antenatal glucocorticoids for 
women at risk of preterm birth: a Cochrane Systematic Review. Am J Obstet Gynecol 206, 187-194. 
Moisiadis, V.G., Matthews, S.G., 2014a. Glucocorticoids and fetal programming part 1: Outcomes. Nat 
Rev Endocrinol 10, 391-402. 
Moisiadis, V.G., Matthews, S.G., 2014b. Glucocorticoids and fetal programming part 2: Mechanisms. Nat 
Rev Endocrinol 10, 403-411. 
Muftuler, L.T., Davis, E.P., Buss, C., Head, K., Hasso, A.N., Sandman, C.A., 2011. Cortical and 
subcortical changes in typically developing preadolescent children. Brain Res 1399, 15-24. 
Muftuler, L.T., Davis, E.P., Buss, C., Solodkin, A., Su, M.Y., Head, K.M., Hasso, A.N., Sandman, C.A., 
2012. Development of white matter pathways in typically developing preadolescent children. Brain Res 
1466, 33-43. 
Noorlander, C.W., De Graan, P.N., Middeldorp, J., Van Beers, J.J., Visser, G.H., 2006. Ontogeny of 
hippocampal corticosteroid receptors: effects of antenatal glucocorticoids in human and mouse. J Comp 
Neurol 499, 924-932. 
O'Donnell, K.J., Glover, V., Jenkins, J., Browne, D., Ben-Shlomo, Y., Golding, J., O'Connor, T.G., 2013. 
Prenatal maternal mood is associated with altered diurnal cortisol in adolescence. 
Psychoneuroendocrinology 38, 1630-1638. 
Raudenbush, S.W.B., A.S., 2002. Hierarchical Linear Models: Applications and Data Analysis Methods. 
SAGE Publications, Inc., Thousand Oaks, California. 
Rosmond, R., Bjorntorp, P., 1998. Blood pressure in relation to obesity, insulin and the hypothalamic-
pituitary-adrenal axis in Swedish men. J Hypertens 16, 1721-1726. 
Ruttle, P.L., Shirtcliff, E.A., Serbin, L.A., Fisher, D.B., Stack, D.M., Schwartzman, A.E., 2011. 
Disentangling psychobiological mechanisms underlying internalizing and externalizing behaviors in 
youth: longitudinal and concurrent associations with cortisol. Horm Behav 59, 123-132. 
Sanchez, M.M., Young, L.J., Plotsky, P.M., Insel, T.R., 2000. Distribution of corticosteroid receptors in 
the rhesus brain: relative absence of glucocorticoid receptors in the hippocampal formation. J Neurosci 
20, 4657-4668. 
Saridjan, N.S., Henrichs, J., Schenk, J.J., Jaddoe, V.W., Hofman, A., Kirschbaum, C., Verhulst, F.C., 
Tiemeier, H., 2014a. Diurnal cortisol rhythm and cognitive functioning in toddlers: the Generation R 
Study. Child Neuropsychol 20, 210-229. 
Saridjan, N.S., Velders, F.P., Jaddoe, V.W., Hofman, A., Verhulst, F.C., Tiemeier, H., 2014b. The 
longitudinal association of the diurnal cortisol rhythm with internalizing and externalizing problems in 
pre-schoolers. The Generation R Study. Psychoneuroendocrinology 50, 118-129. 
Shirtcliff, E.A., Allison, A.L., Armstrong, J.M., Slattery, M.J., Kalin, N.H., Essex, M.J., 2012. 
Longitudinal stability and developmental properties of salivary cortisol levels and circadian rhythms from 
childhood to adolescence. Dev Psychobiol 54, 493-502. 
Stalder, T., Baumler, D., Miller, R., Alexander, N., Kliegel, M., Kirschbaum, C., 2013. The cortisol 
awakening response in infants: ontogeny and associations with development-related variables. 
Psychoneuroendocrinology 38, 552-559. 
Ter Wolbeek, M., Kavelaars, A., de Vries, W.B., Tersteeg-Kamperman, M., Veen, S., Kornelisse, R.F., 
van Weissenbruch, M., Baerts, W., Liem, K.D., van Bel, F., Heijnen, C.J., 2015. Neonatal glucocorticoid 
treatment: long-term effects on the hypothalamus-pituitary-adrenal axis, immune system, and problem 
behavior in 14-17 year old adolescents. Brain Behav Immun 45, 128-138. 
Volpe, J.J., 2008. Neurology of the Newborn, 5 ed. Elsevier, Philedelphia. 
Wechsler, D., 1997. Wechsler Adult Intelligence Scale—Third Edition. The Psychological Corporation., 
San Antonio, TX. 
Wechsler, D., 2002. Wechsler Preschool and Primary Scale of Intelligence. The Psychological 
Corporation, San Antonio, TX. 
Wilhelm, I., Born, J., Kudielka, B.M., Schlotz, W., Wust, S. (2007). Is the cortisol awakening rise a 
response to awakening? Psychoneuroendocrinology 32(4), 358-66.  
  
Figure Legends: 
Figure 1: Salivary cortisol levels across the day for children treated (gray bars) or not treated (patterned 
bars) with antenatal betamethasone.  
Figure 2: HLM model of the unique contribution of antenatal betamethasone exposure on diurnal cortisol 
trajectories. Even after accounting for covariates, children treated with betamethasone had an atypical 
decline in cortisol levels after awakening (gray line).  In contrast, children without antenatal 
glucocorticoid treatment showed a typical peak in cortisol after awakening followed by a gradual decrease 
in cortisol across the day (black line).  
 
  
Table 1: Descriptive information for children in the study sample 
 Child Characteristics Betamethasone 
Group (n=19) 
Comparison 
Group (n=61) 
P 
GA at first dose (weeks)b 30.1 ( 3.1) N/A N/A 
Days between first dose and delivery b 59.5 (22.1) N/A N/A 
Gestational age at birth (weeks) b 38.5 ( 0.9) 39.3 ( 1.4) 0.01 
Birth weight (grams) b 3475 (465.5) 3414 (417.7) 0.59 
Birth weight percentile b 60.1 (26.8) 51.1 (25.8) 0.19 
Birth order (% firstborn) a 7 (36.8%) 19 (31.1%) 0.78 
Race/Ethnicitya          0.83 
     Hispanic 9 (47.4%) 33 (51.6%)  
     Non-Hispanic White 5 (26.3%) 15 (23.4%)  
     Other 5 (26.3%) 13 (20.3%)  
Sex (% Male) a 8 (42.1%) 33 (54.1%) 0.44 
Apgar score at 5-minutes b 8.95 (0.23) 8.90 (0.44) 0.65 
Age at assessment (yrs) b 8.07 (1.19) 8.22 (1.42) 0.68 
Physical health score 0.57 (0.42) 0.61 (0.56) .74 
WISC-IV: PRI 102.0 (11.5) 97.4 (13.2) 0.17 
Life events score 6.9 (3.1) 7.4 (2.8) 0.56 
Time of Awakening b  7:19am (1:08) 7:08am (0:57) 0.52 
a: N(%). b: Mean (SD). Betamethasone group n=19, except gestational age at first dose and days between 
first dose and delivery where n=17. Comparison group n=61, except birth weight and Apgar score where 
n=60 and time of awakening where n=59.  
  
Table 2: Descriptive information for mothers 
 Maternal Demographics Betamethasone 
Group (n=19) 
Comparison 
Group (n=61) 
P 
Maternal age at delivery (yrs) b 30.2 (5.5) 29.3 (6.9) 0.60 
Living as married or cohabitatinga 
Cohabitating with baby’s fathera 
18 (94.7%) 
18 (94.7%) 
53 (86.9%) 
48 (78.7%) 
0.68 
0.17 
Highest level of educationa   0.49 
     High School or Less 4 (21.1%) 22 (34.4%)  
     Some College or certificate 10 (52.6%) 26 (40.6%)  
     Bachelor degree or higher 5 (26.3%) 13 (20.3%)  
Annual household incomea   0.52 
     $0-$50,000 8 (42.1%) 26 (44.1%)  
     $50,001-$100,000 7 (36.8%) 13 (22.0%)  
     Over $100,000 4 (21.1%) 17 (28.8%)  
WAIS: POI score b 95.3 (14.1) 93.4 (17.7) 0.67 
BDI-II total score b 6.2 (6.3) 6.1 (6.4) 0.97 
a: N(%). b: Mean (SD). Comparison group n=61, except for household income where n=56. 
  
Table 3: Betamethasone exposure and gestational age at birth predict cortisol rhythm in children. 
Effect Estimate SE T 
Growth Curve Model    
     Average Awakening levels 5.37 0.57 9.50*** 
     Average CAR -0.12 0.85 -0.14 
     Average Diurnal Slope -0.34 0.04 -9.11*** 
Betamethasone Model    
     Predicting Awakening levels    
         Intercept 5.27 0.67 7.92*** 
         Betamethasone 0.37 1.24 0.30 
     Predicting CAR    
         Intercept 0.71 1.01 0.70 
         Betamethasone -3.44 1.64 -2.10* 
     Predicting Diurnal Slope    
         Intercept -0.38 0.04 -8.71*** 
         Betamethasone 0.19 0.07 2.63** 
Multivariate Model    
     Predicting Awakening levels    
         Intercept 5.20 0.60 8.66*** 
         Betamethasone 0.74 1.23 0.61 
         Gestational age at birth 0.70 0.44 1.57 
         Time of awakening -0.94 0.16 -5.87*** 
     Predicting CAR    
         Intercept 1.01 0.97 1.04 
         Betamethasone -4.77 1.72 -2.78** 
         Gestational age at birth -1.48 0.60 -2.46* 
     Predicting Diurnal Slope    
         Intercept -0.40 0.04 -9.03*** 
         Betamethasone 0.23 0.08 2.94** 
         Gestational age at birth 0.04 0.03 1.67^ 
*: p<0.05; **: p<0.01; ***: p<0.001. CAR: Cortisol Awakening Response. All predictors for each model 
are represented in the table.  
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